Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 18199038.
- Also identified by DOI 10.1086/526775.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.
Medical subject headings
- Anti-Bacterial Agents
- Drug Resistance, Multiple, Bacterial
- Gram-Negative Bacteria
- Gram-Negative Bacterial Infections
- Minocycline